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Chronic cancer-related fatigue (CF) is a common and distressing condition in a subset of
cancer survivors and common also after successful treatment of malignant lymphoma. The
etiology and pathogenesis of CF is unknown, and lack of biomarkers hampers development
of diagnostic tests and successful therapy. Recent studies on the changes of amino acid lev-
els and other metabolites in patients with chronic fatigue syndrome/myalgic encephalopathy
(CFS/ME) have pointed to possible central defects in energy metabolism. Here we report a
comprehensive analysis of serum concentrations of amino acids, including metabolites of
tryptophan, the kynurenine pathway and vitamin B6 in a well characterized national Norwe-
gian cohort of lymphoma survivors after high-dose therapy and autologous stem cell trans-
plantation. Among the 20 standard amino acids in humans, only tryptophan levels were
significantly lower in both males and females with CF compared to non-fatigued survivors, a
strikingly different pattern than seen in CFS/ME. Markers of tryptophan degradation by the
kynurenine pathway (kynurenine/tryptophan ratio) and activation of vitamin B6 catabolism
(pyridoxic acid/(pyridoxal + pyridoxal 5’-phosphate), PAr index) differed in survivors with or
without CF and correlated with known markers of immune activation and inflammation, such
as neopterin, C-reactive protein and Interleukin-6. Among personal traits and clinical find-
ings assessed simultaneously in participating survivors, higher neuroticism score, obesity
and higher PAr index were significantly associated with increased risk of CF. Collectively,
these data point to low grade immune activation and inflammation as a basis for CF in lym-
phoma survivors.







Citation: Fosså A, Smeland KH, Fluge Ø, Tronstad
KJ, Loge JH, Midttun Ø, et al. (2020) Metabolic
analysis of amino acids and vitamin B6 pathways in
lymphoma survivors with cancer related chronic
fatigue. PLoS ONE 15(1): e0227384. https://doi.
org/10.1371/journal.pone.0227384
Editor: Gilles J. Guillemin, Macquarie University,
AUSTRALIA
Received: July 28, 2019
Accepted: December 17, 2019
Published: January 10, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0227384
Copyright: © 2020 Fosså et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The data which have
been included with the paper and its Supporting
Information is the full extent of the data allowed to
be shared in accordance with Norwegian
Introduction
Persistent fatigue is a subjective experience of tiredness, exhaustion and lack of energy that has
a negative impact on daily life and functioning. It is a common symptom in a wide variety of
disorders, for instance, in patients with inflammatory or infectious diseases, depression disor-
der and cancer [1–3]. Together with post-exertional malaise, a marked aggravation of symp-
toms after exercise, fatigue is also the hallmark symptom in patients with chronic fatigue
syndrome/myalgic encephalopathy (CFS/ME) [4].
Whereas acute fatigue is a healthy, adaptive response to physical or mental exertion and
typically resolves after rest or sleep, persistent fatigue is often disproportional to exerted activi-
ties and is generally not completely alleviated after a period of rest. The pathophysiological
changes leading to persistent fatigue in different diseases are poorly understood and no specific
treatment is available to ameliorate fatigue in affected individuals.
Chronic cancer-related fatigue (CF, defined as pronounced fatigue for� 6 months) is a
common and distressing late effect after cancer treatment affecting patients treated for both
solid cancers and hematological malignancies [1, 5, 6]. CF has been described in 25–35% of
long-term survivors of breast cancer, lymphoma or testicular cancer in Norway, compared to
11% in a national representative population [7–10]. These patients are cured of their malig-
nancies but may suffer from other late effects where fatigue may be an associated symptom.
The etiology and pathophysiology of CF in cancer survivors is largely unknown, though evi-
dence suggests it may be multifactorial, influenced by demographic, somatic and psychological
factors [5, 11]. The incidence varies with the type of cancer and treatment given and seems to
increase in the presence of psychological discomfort such as anxiety, pessimism, low mood or
depression. Somatic comorbidities such as endocrine abnormalities, pulmonary dysfunction
or cardiovascular disease may predispose patients to CF [12–14]. In the care of survivors with
CF, it is important to rule out and treat such coexisting symptoms and conditions. Some stud-
ies point to an ongoing low grade inflammatory process in patients with CF after breast cancer
or lymphoma [15–17].
Despite knowledge of these associated conditions, the absence of an etiological and patho-
physiological understanding of CF limits the ability to diagnose and treat CF. For example; it is
not known whether the mechanisms underlying fatigue in different medical conditions are
similar. Recently, large scale metabolic studies in CFS/ME have revealed underlying defects
related to key pathways of metabolism that discriminate patients with CFS/ME from healthy
individuals, providing a possible basis for future diagnostic tests and therapeutic interventions
[18–20]. We and others found in patients with CFS/ME that circulating concentrations of
amino acid and other metabolites fueling energy generation in the tricarboxylic acid were
altered and energy metabolism hampered [18, 19]. Such observations have allowed generation
of hypotheses as to mechanisms driving fatigue and associated symptoms in CFS/ME [21].
On this background, we recently assessed the prevalence of CF in a national cohort of adult
lymphoma survivors treated with high-dose therapy and autologous stem cell transplantation
(HDT-ASCT) [22]. We investigated associations between CF and disease- and treatment-
related characteristics, psychological factors and objectively measured somatic health, includ-
ing cardiorespiratory fitness and selected cytokines. CF is a prevalent long term condition
affecting about 30% of these survivors and our data suggest ongoing low grade inflammation
as a pathogenic mechanism. With the aim to explore further the underlying metabolic defects
driving CF in cancer survivors, we now extend these studies to metabolic analyses as previ-
ously done in CFS/ME, comparing individuals with or without CF. We report here metabolic
analyses in lymphoma survivors with a median follow-up of 10 years after HDT-ASCT.
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Patients and methods
Patients
The study was part of a national multicenter cross-sectional study performed in 2012–2014
[23]. All survivors treated with HDT-ASCT for lymphoma in Norway from 1987 to 2008, aged
�18 years at HDT-ASCT, resident in Norway at survey, in remission and not currently under-
going systemic therapy for active malignancy, were eligible as described earlier (n = 399) [23].
The survivors were identified through treatment records and registries at each participating
center. Eligible survivors were invited by mail to complete a questionnaire and attend an out-
patient clinical examination, including blood sampling and exercise testing with measurement
of peak oxygen consumption (VO2peak) [22–24].
The study was approved by the South East Regional Committee for Medical and Health
Research Ethics (approval number 2011/1353 B). Written informed consent was given by all
participants.
Blood was drawn by venous puncture after overnight fasting on the morning of the outpa-
tient clinical examination. Plasma glucose, C-reactive protein (CRP), albumin, triglycerides,
total cholesterol, low and high density lipoprotein cholesterol were measured according to
routine laboratory facilities at each hospital. For serum preparation and later metabolic analy-
ses, tubes without gel were used, allowed to coagulate for 30–60 minutes prior to centrifuga-
tion for 15 minutes at 1000 x g at 4˚C. Serum was aliquoted into sterile tubes and frozen at
-80˚C. Samples were stored at -80˚C and thawed immediately prior to analysis.
Lymphoma- and treatment-related data were obtained from patients’ charts. Treatment of
lymphomas in Norway, including HDT-ASCT, has followed international and national guide-
lines [25]. In the period 1987–1995 the conditioning regimen consisted of total body irradia-
tion (TBI) and high-dose cyclophosphamide, and from 1996 chemotherapy only (BEAM:
carmustine, etoposide, cytarabine and melphalan). The survivors were grouped according to
time of HDT-ASCT: 1987–1995, 1996–2002 and 2003–2008 and primary diagnosis: Hodgkin
lymphoma (HL), aggressive non-Hodgkin lymphoma (NHL) (diffuse large B-cell lymphoma,
T-cell lymphomas, mantle cell lymphoma, Burkitt’s lymphoma and lymphoblastic lymphoma)
and indolent NHL (mostly follicular lymphoma).
Patient reported outcomes and cytokines
Neuroticism was assessed by an abbreviated version of the Eysenck Personality Questionnaire
with six items, with higher score implying more neuroticism [26]. Internal consistency
assessed by Cronbach’s α was 0.79. A 15-item version of the Impact of event scale (IES) was
used to measure post-traumatic symptoms related to HDT-ASCT, consisting of seven items
on intrusion and eight on avoidance, with responses on a six-point frequency scale for each
item [27]. Internal consistencies were 0.91 for intrusion and 0.91 for avoidance. Mental dis-
tress was measured by the Hospital Anxiety and Depression Scale (HADS). Each item was
scored from 0 (not present) to 3 (highly present) [28]. Internal consistencies were 0.82 and
0.87 for the depression and anxiety subscales, respectively.
Chronic fatigue was assessed by the Fatigue Questionnaire which contains 11 items con-
cerning physical (7 items) and mental (4 items) fatigue during the last month, compared with
when the respondent last felt well [29]. Each item has four response alternatives scored from 0
(better) to 3 (much worse). Two additional items cover duration and extent of fatigue.
Responses were dichotomized (0 = 0 and 1; 1 = 2 and 3) and used for case definition, with CF
defined as a sum score of�4 of the dichotomized responses with duration of�6 months.
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Internal consistency (Cronbach’s α) was 0.92 for total fatigue, 0.93 for physical fatigue and
0.80 for mental fatigue, respectively.
Measurements of Interleukin(IL)-6, IL-1β, IL-1Receptor Antagonist (RA) and Tumor
Necrosis Factor(TNF)α in serum have been reported for this cohort previously. As reported,
IL-1β and TNFα levels were not associated with the prevalence of CF and therefore not ana-
lyzed further. IL-6 was analytically undetectable in a substantial number of patients, and there-
fore dichotomized as detectable versus not detectable [22].
Analyses of amino acids, metabolites, B-vitamers and neopterin
All analyses were done by Bevital AS, Bergen, Norway (www.bevital.no). The standard amino
acids (except Arginine (Arg)), ornithine, α-ketoglutaric acid and the tryptophan (Trp) metab-
olite kynurenine (Kyn) were analyzed using gas chromatography–tandem mass spectrometry
(GC-MS/MS), with within and between day coefficient of variation (CV) of 2%–5% [30]. Arg,
homoarginine (hArg), methylated asymmetric or symmetric arginines (ADMA and SDMA)
were analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS), with
within and between day CVs of 3%–12% [31]. Biomarkers related to vitamin B6 status, i.e. pyr-
idoxal 5’-phosphate (PLP), pyridoxal (PL) and 4-pyridoxic acid (PA) and other metabolites of
the kynurenine pathway, i.e. kynurenic acid (KA), anthranilic acid (AA), 3-hydroxykynure-
nine (HK), xanthurenic acid (XA) and 3-hydroxyanthranilic acid (HAA), picolinic acid (Pic),
quinolinic acid (QA), in addition to nicotinic acid (NA), nicotinamide (NAM) and
N1-methylnicotinamide (mNAM) and neopterin were quantified using LC-MS/MS with
within-day and between day CVs of 2–17% [32]. Because the assay includes protein precipita-
tion by trichloroacetic acid, which oxidizes 7,8-dihydroneopterin to neopterin, and the
method measures total neopterin [32, 33].
As markers of inflammation the following indices were derived from the analysed biomarkers:
PAr index was calculated as the ratio of PA divided by the sum of PLP and PL (PA/(PLP+PL)).
PAr efficiently discriminates subjects with high inflammatory status [34, 35]. It is only slightly
influenced by vitamin B6 intake and reflects increased vitamin B6 catabolism during inflamma-
tion. The kynurenine/tryptophan (Kyn/Trp) ratio was calculated from Kyn and Trp concentra-
tions. The Kyn/Trp ratio has been reported to be a marker of cellular immune responses [36, 37].
Statistics
Descriptive statistics including t-tests for normally distributed data, Mann-Whitney U tests for
variables with skewed distributions and Chi-square and Fischer’s exact tests for categorical vari-
ables, were used as appropriate. Correlations are reported as Spearman coefficients (rs). Multi-
variate logistic regression analysis was performed with CF as the dependent variable, including
predictors with p-value<0.10 in univariate analyses. As reported previously, subscales of
HADS were excluded due to high correlation with neuroticism. PAr substituted IL-6 in the
model due to highly significant bivariate correlations. Due to the explorative and hypothesis
generating design of the study, the significance level was set to 0.05, and all tests were two-sided.
Statistical analyses were performed using International business machines Statistical Package
for the Social Sciences version 23. Figures were produced using Stata SE version 15.
Results
Attrition analysis and patient characteristics
Of 399 eligible survivors, 311 (78%) consented and completed the questionnaire (Fig 1). Of
these, 270 attended the clinical examination. Blood tests were taken as specified in the protocol
Metabolic analysis of chronic fatigue
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Fig 1. Patient flow chart.
https://doi.org/10.1371/journal.pone.0227384.g001
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in 258 survivors. For the final analysis, 14 patients with ongoing immune modulatory treat-
ment were excluded (i.e. treatment with anakinra, prednisolone, cyclosporin A or intravenous
immunoglobulins). The 244 (61% of the total) included participants (Table 1) were slightly
older than non-participants, but there was no statistically significant difference regarding age,
sex, observation time, lymphoma type or conditioning regimen. After a median follow-up of
12 years since diagnosis, the prevalence of CF was 32%. The proportions of chronically
fatigued survivors by patient, disease and treatment characteristics, patient reported outcomes
and findings from clinical examination are given in Table 1. There were no differences
between fatigued and non-fatigued survivors concerning glucose, triglycerides or total, high or
low density lipoprotein cholesterol.
Serum amino acid concentrations
Based on findings that serum concentrations of amino acids may reveal defects in energy
metabolism we analyzed serum concentrations of all standard 20 amino acids in survivors
with or without CF (S1 Table). Since there were gender differences for several of the tested
amino acids, the results are reported for the whole groups of survivors and for female and
male patients separately. The only amino acid with a statistically significant difference in
serum concentration was Trp. Survivors with CF had a mean concentration (95% confidence
interval (CI)) of 73.4 (70.5–76.4) μM compared to 77.6 (75.9–79.3) μM in non-fatigued survi-
vors (p = 0.01; Fig 2). Differences were similar in each gender, but did not reach significant p-
values (S1 Table). The concentrations of all other amino acids were similar in survivors with
or without CF, both when analyzed individually or when combined for groups of amino acids
converted to pyruvate (Category I), to acetyl-coenzyme A (Category II) or for the anaplerotic
amino acids (category III) converted to different intermediates of the tricarboxylic acid cycle.
Of the other amino acid related metabolites tested, the only significant difference was seen
for the tricarboxylic acid cycle intermediate α-ketoglutaric acid (S2 Table). Survivors with CF
had a mean concentration (95% CI) 9.2 (8.5–9.7) μM and non-fatigued survivors 8.4 μM (8.2–
8.8; p = 0.02; Fig 2). The difference in serum α-ketoglutaric acid concentration was seen in
both males and females, but not with significant p-values for sexes separately (S2 Table). There
were no differences for metabolites relating to Arg metabolism and endothelial function (Arg,
hArg, ADMA or SDMA) or metabolites relating to the urea cycle (ornithine and urea).
Kynurenine pathway, vitamin B6 markers and neopterin
Since Trp is mainly degraded by the kynurenine pathway and this pathway is subject to regula-
tion by inflammatory signals, metabolites along this degradation pathway were analyzed (S3
Table) [37]. There were again no clear differences in the concentration of the different Trp
metabolites according to the presence of CF in the whole group of survivors. However, the
ratio of Kyn to Trp concentrations was higher in fatigued (mean 0.029; 95% CI 0.025–0.033)
than non-fatigued survivors (mean 0.026; 95% CI 0.025–0.028) with a borderline significance
level of p = 0.06 (S3 Table; Fig 3). Further, there were indications of change for two of the
intermediates in this pathway. The level of HK tended to be higher (p = 0.07) in the patients
with CF (63.2 (0–135.5) μM) compared to those without CF (56.1 (7.9–104.3) μM). When sep-
arating the genders, a significantly higher HK level was observed among men with CF (64.9
(0–143.1) μM versus 54.5 (12.3–96.7) μM, p = 0.04), but not women. The level of HAA tended
to be lower (p = 0.09) in the CF group (52.5 (11.2–93.7) μM) compared to those without CF
(57.1 (19.7–94.5) μM). This effect was primarily due to a trend of difference between the
female patients with and without CF (45.3 (13.4–77.2) μM versus 52.5 (14.7–90.3) μM,
p = 0.07)
Metabolic analysis of chronic fatigue
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Table 1. Patient characteristics according to chronic fatigue.




Median age at diagnosis/years (range) 42 (10–65) 40 (17–64) 0.66
Age at survey/year (range) 56 (25–76) 55 (24–77) 0.37
Median time diagnosis to survey/months (range) 152 (49–408) 125 (43–367) 0.54
Median time diagnosis to HDT-ASCTa/months (range) 15 (2–257) 15 (2–272) 0.99
Lymphoma type 0.20
Hodgkin lymphoma 31 21
Aggressive Non-Hodgkin lymphoma 121 47





Ann Arbor stage at diagnosis� 0.46
I/II 50 27
III/IV 116 50
B-symptoms at diagnosis† 0.48
No 110 47
Yes 54 29
High dose regimen 0.57









Relapse after HDT-ASCT 0.30
No 138 59
Yes 29 18
Allogeneic SCTd after HDT-ASCT 0.47
No 162 73
Yes 5 4
Body mass index (kg/m2) 0.02
<30 (not obese) 150 60
�30 (obese) 17 17
Median score HADSe A (range) 3 (0–12) 5 (0–19) p<0.001
Median score HADS D (range) 1 (0–12) 5 (0–15) p<0.001
Median neuroticism score (range) 0 (0–6) 3 (0–6) p<0.001
Median impact of event score (range) 5 (0–60) 13 (0–62) p<0.001
Mean CRPf/mg/L (SDg) 5.5 (18.5) 3.6 (6.6) 0.22
Mean plasma glucose/mmol/L (SD) 5.9 (1.4) 5.7 (0.9) 0.32
Mean triglycerides/mmol/L (SD) 1.4 (0.9) 1.3 (0.6) 0.20
(Continued)
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Several key enzymes of the kynurenine pathway require PLP as a cofactor and are regulated
by inflammatory cytokines [37]. α-Ketoglutaric acid is also connected to glutamic acid metab-
olism through a PLP-dependent transamination reaction. Whereas individual vitamin B6
metabolites were not significantly different in fatigued versus non-fatigued lymphoma survi-
vors, the PAr index was significantly higher in the CF group (mean 0.638 (95% CI 0.543–
0.734)) compared to the group without CF (0.491 (0.449–0.534); p = 0.006; Fig 3). The differ-
ence was present and significant in both male and female survivors (S4 Table).
Neopterin is a catabolic product of guanosine triphosphate, a purine nucleotide and belongs
to the chemical group known as pteridines. It is synthesized by human macrophages upon
stimulation with the cytokine interferonγ and serves as a marker of cellular immune activation
[38]. The mean (95% CI) serum concentration of neopterin in fatigued survivors was higher
(27.1 (23.1–31.2) nM) than in the non-fatigued counterpart (23.1 (21.6–24.7) nM) with a bor-
derline significance level of p = 0.07 (Fig 3). The difference was more prominent in male survi-
vors than in females (S4 Table).
Kyn/Trp ratio, PAr index and neopterin concentrations were positively and significantly
correlated with rs values of 0.57 for PAr index versus neopterin (p<0.01), 0.60 for PAr Index
versus Kyn/Trp (p<0.01) and 0.80 for neopterin versus Kyn/Trp (p<0.01, S1 Fig). All three
correlated with CRP levels with rs 0.28 for PAr index versus CRP (p<0.001), 0.12 for neopterin
versus CRP (p = 0.06) and 0.14 for Kyn/Trp versus CRP (p = 0.03).
Since the prevalence of CF was associated with the levels of IL-6 and IL-1RA (Table 1) we
analyzed the distribution of the three markers PAr index, Kyn/Trp ratio and neopterin levels
according to the levels of these cytokines. All three markers were significantly higher in survi-
vors with detectable IL-6 levels in serum compared to patients with no detectable serum IL-6
(p<0.001 for all three comparisons; Fig 4). The plasma levels of IL-1RA were significantly
Table 1. (Continued)
No chronic fatigue (n = 167 Chronic fatigue (n = 77) P
Mean cholesterol/mmol/L (SD) 5.3 (1.2) 5.4 (1.2) 0.33
Mean LDLh cholesterol/mmol/L (SD) 3.2 (1.1) 3.5 (1.1) 0.08
Mean HDLi cholesterol/mmol/L (SD) 1.5 (0.5) 1.5 (0.5) 0.69
Mean albumin/g/L (SD) 43.5 83.3) 44.1 (2.8) 0.14
Mean VO2
j peak/L/min (SDh) 2.29 (0.72) 2.04 (0.66) 0.02
Interleukin-6 detectable‡ 84 53 0.005
Interleukin-1RAk/pg/mL (SD)‡ 66.0 (96.5) 42.0 (55.9) 0.04
a High dose therapy with autologous stem cell transplantation
b Total body irradiation
c.Carmustine, etoposide, cytarabine and melphalan
dStem cell transplantation






kReceptor Antagonist. P-values obtained by X2-test for categorical variables and independent t-test or Mann-Whitney (skewed data) for continuous variables.
�One
† 4, and
‡2 patients missing information.
https://doi.org/10.1371/journal.pone.0227384.t001
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correlated with PAr index (rs of 0.14; p = 0.03), Kyn/Trp ratio (rs of 0.16; p = 0.016) and neop-
terin (rs of 0.14; p = 0.03).
Body mass index, nutritional status and vitamin supplements
To check for possible confounding influences of obesity, nutritional status and supplementary
intake of vitamins subgroup analyses were performed. BMI and triglyceride levels correlated
significantly with neither Trp levels, Kyn/Trp ratio, PAr index nor neopterin concentrations.
Albumin levels, frequently used as a marker of nutritional status despite being also associated
with an inflammatory response, were significantly correlated with Trp concentration (rs =
0.340; p<0.001), neopterin (rs = -0.262; p<0.001), Kyn/Trp ratio (rs = -0.350; p<0.001) and
PAr index (rs = -0.352; p<0.001). Albumin was not correlated with BMI or triglycerides, but
negatively correlated with CRP (rs = -0.300; p<0.001). 8 patients reported regular intake of
vitamin B supplements, in most casesmixtures of different vitamins including vitamin B6. Of
these 8 patients, 4 were fatigued and there were no statistically significant differences com-
pared to those not taking vitamin B supplements neither for Trp and neopterin concentra-
tions, Kyn/Trp ratio nor PAr index.
Fig 2. Concentrations of tryptophan (A) and α-ketoglutaric acid (B) in survivors with and without chronic fatigue. Blue dots represent individual patients; red
lines represent mean values in each group. p< 0.05 for both comparisons.
https://doi.org/10.1371/journal.pone.0227384.g002
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Fig 3. Kyn/Trp ratio (A), PAr index (B) and neopterin (C) in survivors with or without chronic fatigue. Blue dots represent individual patients; red lines represent
mean values in each group. P = 0.06 for Kyn/Trp ration, p = 0.006 for PAr index and p = 0.07 for neopterin.
https://doi.org/10.1371/journal.pone.0227384.g003
Fig 4. Kyn/Trp ratio (A), PAr index (B) and neopterin (C) in survivors with or without detectable IL-6 levels. Blue dots represent individual patients; red lines represent
mean values in each group. p< 0.001 for all three comparisons.
https://doi.org/10.1371/journal.pone.0227384.g004
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Logistic regression with chronic fatigue as dependent variable
Logistic regression with CF as dependent variable was performed as described previously [22].
Factors associated with CF with p� 0.10 in univariate analyses were entered in the model, but
due to high correlation with each other, detectable IL-6 levels were replaced by PAr values in
the model (S5 Table). In multivariable analysis, higher neuroticism score (Odds ratio (OR) =
1.50, 95% CI 1.21–1.87, p<0.001), obesity (OR = 3.11, (1.22–7.97), p = 0.02) and higher PAr
values (OR = 3.62, (1.05–12.46), p = 0.04) were associated with increased risk of CF.
Discussion
We report metabolic profiling of lymphoma survivors after HDT-ASCT with or without CF
and well characterized in terms of other associated late complications, both somatic and psy-
chological [22]. The range of analyzed metabolites was focused on amino acids and pathways
related to inflammation, immune activation and vitamin B6.
The study was planned to evaluate possible changes in amino acid concentrations in survi-
vors with CF as previously described in patients with CFS/ME [18, 19]. In CFS/ME these
changes have been indicative of a defect in the tricarboxylic acid cycle, and have been postu-
lated to play a role in the pathogenesis of this disorder. Importantly, the defects in energy
metabolism could be responsible for post exertional malaise, a key clinical finding associated
with fatigue in CFS/ME. No similar differences in amino acid concentrations were found
when we compared lymphoma survivors after HDT-ASCT that suffer from CF to survivors
without CF. The blood samples were taken under standardized fasting conditions. Since we
are interested in diagnostic biomarkers of CF, potentially with relevance to pathogenic mecha-
nisms, we deliberately chose to compare survivors with or without fatigue. As gender differ-
ences have been described in CFS/ME, we did all analyses in males and females separately.
Since levels of amino acids and vitamins of the B- family may depend on nutritional status and
intake of dietary supplements, relevant differences in serum concentrations were analyzed also
with regard to BMI, other proposed blood markers of nutrition and against self-reported
intake of vitamin supplements. The absence of similar changes of serum amino acid levels in
the present study indicates different pathomechanisms in lymphoma survivors with CF and
patients with CFS/ME, explaining also the clinical differences between the two conditions, i.e.
female preponderance and presence of post exertional malaise, a marked aggravation of symp-
toms after exercise, in CFS/ME [4].
Interestingly, the difference in Trp levels observed in lymphoma survivors with or without
CF (mean values 73.4 μM and 77.6 μM, respectively), were also seen when comparing patients
with CFS/ME (mean concentration 73.4 μM) to healthy age matched individuals (77.8 μM)
[19]. For the other amino acids tested, the lymphoma survivors resemble more closely the
healthy control subjects of the latter study, irrespective of a diagnosis of CF or not [19].
Compared to their non-fatigued counterparts, survivors with CF are characterized by meta-
bolic changes that may be associated with a low grade inflammatory status. The essential
amino acid Trp is the precursor of melatonin and serotonin, and has received much attention
in investigations of depression and other psychiatric disorders [39, 40]. Trp is mainly catabo-
lized along the kynurenine pathway that produces intermediate compounds, collectively
referred to as kynurenines, with a variety of effects, including neuro- and immunomodulation
[37]. Metabolites of the kynurenine pathway also serve as precursors for nicotinamide adenine
dinucleotide synthesis and thereby play a role in energy homeostasis. The hepatic enzyme tryp-
tophan-2,3-dioxygenase (TDO) and the more widely expressed indolamine 2,3-dioxygenases
(IDO) 1 and 2 catalyze the oxidative cleavage of Trp to Kyn, the first and rate limiting step of
the pathway [41, 42]. The ratio of Kyn to Trp has been proposed as a marker of these
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enzymatic reactions, but other factors, especially the activity of downstream enzymes metabo-
lizing Kyn are also important in determining the Kyn/Trp ratio [41]. Both TDO and IDO have
been implicated in a variety of disease states, including cancer and inflammation [42]. Of note,
TDO activity in liver may be induced by cortisol and IDO and other enzymes of the kynure-
nine pathway may be activated by proinflammatory cytokines such as Interferonγ, IL-6 or
TNFα [37, 43, 44]. We found that the Kyn/Trp ratio in all lymphoma survivors analyzed was
significantly correlated with other markers of immune activation and inflammation, such as
measurable levels of IL-6, neopterin and CRP. There was a trend towards higher Kyn/Trp
ratios in survivors with CF but the difference did not reach the predefined significance level.
We also found trends for different levels of two intermediates in the kynurenine pathway (HK
and HAA), suggesting that the lower Trp level in serum of survivors with CF possibly is associ-
ated with altered flux through this pathway. Apparently, this pathway may also be site for gen-
der-specific effects, as the effect on HK primarily was driven by the female patients (p = 0.04)
whereas the effect on HAA primarily was associated with male patients (p = 0.07). Such effects
may be explained by specific effects on the enzymes involved in this pathway, and changes in
the different metabolic routes kynurenine may take. In summary, it can be speculated that low
grade immune activation and inflammation cause a metabolic shift involving increased drain-
age of Trp from blood, through effects on the kynurenine pathway. Changes in kynurenine
metabolism and elevation of the Kyn/Trp ratio are also found in chronic diseases where low
grade inflammation is assumed to be essential in the pathogenesis, such as cardiovascular dis-
ease, inflammatory bowel disease, obesity and depression [45–48].
Similarly, we observed changes in the metabolism of vitamin B6 in fatigued lymphoma sur-
vivors. PLP, the active vitamer, serves as a cofactor for more than 150 enzymes including sev-
eral of the enzymes involved in the kynurenine pathway. In recent years, the important
function of vitamin B6 homeostasis in inflammation and immune responses in humans has
attracted much interest [37]. Circulating concentrations of PLP show inverse correlations with
risk and severity of a variety of diseases such as cardiovascular disease, cancer, rheumatoid
arthritis and inflammatory bowel disease, all conditions in which inflammation is believed to
play a key role in pathogenesis or disease progression. Blood levels of PA, the catabolite of
PLP, seem positively correlated to markers of immune activation. Thus the index PAr, i.e. PA/
(PL+PLP), has been introduced as a robust marker that reflects key processes related to an
individual’s vitamin B6 homeostasis [49]. The PAr index is less influenced by smoking, renal
function and vitamin B6 intake compared to levels of individual B6 vitamers, and is reported
to discriminate efficiently patients with a high inflammatory state [49]. We found that survi-
vors with CF had significantly higher PAr values than non-fatigued individuals, and that the
PAr values where positively correlated with other markers of immune activations, such as
measurable levels of IL-6, neopterin, CRP and the Kyn/Trp ratio.
Analyzing the same cohort of lymphoma survivors, we have previously reported that detect-
able levels of IL-6 in serum are independent determinants of CF [22]. The high correlation of
IL-6 levels and both Kyn/Trp ratio, PAr index and neopterin indicate that the metabolic
changes we describe are reflective of inflammation and/or immune activation in survivors
with CF. PAr index was associated with the risk of CF in multivariate analysis when used inde-
pendently of the other markers of inflammation or immune activation.
The association of indicators of low-grade inflammation and symptoms of CF does not
allow a conclusion as to the causal direction. It could be that inflammatory processes induce
fatigue in a subset of survivors, but alternatively, secondary effects of being fatigued may result
in similar metabolic changes. For instance, it could be hypothesized that activation of the
hypothalamus-pituitary-adrenal axis in survivors with CF may contribute to inflammation
and cortisol induced TDO activation in the liver.
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The changes in Trp, Kyn/Trp and PAr index in CF reported herein are novel observations
and hypothesis generating, and as such, need to be validated in independent cohorts of cancer
survivors. Before validation, important limitations in our observations need to be acknowl-
edged. Our cohort consists of large number of survivors after high dose therapy for lymphoma
only, all in remission at the time of analysis. The cohort is still heterogeneous in terms of lym-
phoma entities, additional therapy for lymphoma relapse after high dose therapy and in terms
of other medical complications after treatment. The metabolic changes observed do not appear
to be useful for development of diagnostic tests, neither alone nor in combinations. All differ-
ences of individual levels of amino acids, their metabolites or B6 vitamers were modest and
concentrations in both fatigued and non-fatigued survivors were mostly within the normal
range. There was also considerable overlap between the groups of survivors in each of the
metabolites of interest, both Trp levels, Kyn/Trp ratios, individual levels of different kynure-
nins and the PAr index. Repeating the analyses for differences between fatigued and non-
fatigued survivors after omitting possible outliers by the interquartile range rule, did however
not alter the conclusion; levels of Trp, alpha-ketoglutarate and the PAr Index remained signifi-
cantly associated with CF and Kyn/Trp ratios were of borderline significance only. Further-
more, we have analyzed only serum levels, and analyses of other compartments, such as
intracellular levels in specific organs or cells, or other extracellular compartments such as cere-
brospinal fluid, may be more informative. Due to the complex interplay of metabolic and
immune pathways, more sophisticated analyses of a number of different markers together,
such as network analyzes, may also be warranted [50].
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